1. New Agents in Development for Sepsis: Any Reason for Hope?

   • Philippe Vignon
   • Pierre-François Laterre
   • Bruno François

   Leading Article 20 September 2020 Pages: 1751 - 1761

   

2. Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics

   • Simona Cernea
   • Lorena Dima
   • Peter Manu

   Therapy in Practice 15 September 2020 Pages: 1763 - 1781

3. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions

   • Christoph Jakob Ackermann
   • Helen Adderley
   • Raffaele Califano

   Review Article 28 September 2020 Pages: 1783 - 1797

   

4. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent

   • Mario Cazzola
   • Clive Page
   • Maria Gabriella Matera

   Review Article Open access 06 October 2020 Pages: 1799 - 1809

   

5. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars

   • Megan E. Tesch
   • Karen A. Gelmon

   Review Article 06 October 2020 Pages: 1811 - 1830

   

6. Efficacy of Montelukast in Allergic Rhinitis Treatment: A Systematic Review and Meta-Analysis

   • Madhusudhan Krishnamoorthy
   • Norhayati Mohd Noor
   • Baharudin Abdullah

   Systematic Review 11 September 2020 Pages: 1831 - 1851

   

7. Risdiplam: First Approval

   • Sohita Dhillon

   AdisInsight Report 12 October 2020 Pages: 1853 - 1858

   

8. Imlifidase: First Approval

   • Zaina T. Al-Salama

   AdisInsight Report 15 October 2020 Pages: 1859 - 1864

   

9. Pralsetinib: First Approval

   • Anthony Markham

   AdisInsight Report 02 November 2020 Pages: 1865 - 1870

   

10. Correction to: Oliceridine: First Approval

    • Anthony Markham

    Correction 19 October 2020 Pages: 1871 - 1871

11. Correction to: Triheptanoin: First Approval

    • Matt Shirley

    Correction Open access 22 October 2020 Pages: 1873 - 1873